Here are the 424B prospectus supplements from Kymera Therapeutics, Inc. (KYMR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow KYMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KYMR filings page.
Kymera Therapeutics is registering for resale up to 31,385,079 shares of its common stock. This amount consists of 18,819,826 shares plus up to 12,565,253 shares issuable upon exercise of pre-funded warrants, and the registration is to permit resale by the selling stockholders.
The registration is a resale registration under a registration rights agreement; Kymera states it will not receive proceeds from secondary sales, although cash exercises of the pre-funded warrants would yield proceeds equal to the $0.0001 exercise price per share. The prospectus cites February 26, 2026 and reports the registered shares represent approximately 38% of outstanding shares as of February 20, 2026.
Kymera Therapeutics filed a prospectus supplement to sell up to $500,000,000 of common stock in an at-the-market offering through TD Securities (USA) LLC (TD Cowen).
The prospectus states TD Cowen will act as sales agent and may sell shares in negotiated transactions, block trades or on Nasdaq, with compensation up to 3.0% of gross proceeds. The document uses an illustrative price of $91.01 per share (last reported sale price on February 24, 2026) and assumes 5,493,901 shares for illustrative proceeds of $500.0 million. Shares outstanding were 81,323,532 as of December 31, 2025. The company states proceeds, if any, would be used to fund research and clinical development, and for working capital and general corporate purposes.